Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Dako recently introduced in the United States its instant quality in situ hybridization, or IQISH, technology, which will reduce the turnaround time for cancer evaluation from two days to three and a half hours. HER2 IQFISH PharmDx, a fluorescence in situ hybridization assay, is the first product approved by the FDA that uses IQISH technology, which is based on the company’s fast IQISH hybridization buffer chemistry.
March 2013—Great Basin Corp., a privately held molecular diagnostics company that develops sample-to-result solutions, has raised $9.5 million in series B funding. The funding was led by private investors and will be used to expand manufacturing, fund research and development, and expand global commercialization efforts.
Tosoh Bioscience’s ST AIA-Pack 25-OH vitamin D assay is for use on most of the company’s AIA system analyzers. Vitamin D measurement is intended as an aid in the determination of vitamin D sufficiency.
Streck’s A1c-Cellular HbA1c control with intact red blood cells is now assayed for Roche Diagnostics’ Cobas c311. A1c-Cellular tests the entire HbA1c procedure, including the lysing of the red blood cell. This step ensures that the entire system—instrument and reagents—is working properly and providing accurate patient results. The control is easy to use; it does not require reconstitution, which reduces the potential for human error.
Eppendorf North America’s epMotion M5073 and P5073 workstations automate and simplify complex, labor-intensive pipetting tasks, saving time and improving the reliability and reproducibility of results.
Thermo Fisher Scientific’s Prelude sample preparation and liquid chromatography (SPLC) system was developed to make analysis of target compounds in complex biological matrices routine for clinical research and forensic toxicology laboratories.
Randox Laboratories’ Acusera 24.7 live online is a Web-based interlaboratory data-management program to complement Acusera third-party quality controls and improve quality control processes within the clinical laboratory, while also helping to interpret QC results.
Inova Diagnostics’ Bio-Flash rapid-response chemiluminescent analyzer is for use by clinical reference and hospital laboratories. Bio-Flash and the company’s Quanta Flash reagents are for autoimmune disease diagnostic testing.
LabCorp recently announced that its biorepository has been accredited by the College of American Pathologists.
Abbott and BioView have entered into an agreement in which BioView will develop automated digital-imaging software for use with Abbott’s molecular diagnostic test to detect rearrangements of the ALK gene in patients with advanced non-small cell lung cancer. The software scans lung tissue specimens that have been tested for the ALK gene rearrangement with Abbott’s fluorescence in situ hybridization technology.
